A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy
This clinical trial is testing a new gene therapy called Libmeldy for Metachromatic Leukodystrophy (MLD), a serious inherited condition. The study has two main goals: first, to ensure the treatment is safe, looking for any side effects from the preparation for the therapy and the gene therapy itself. Second, it aims to see how well the treatment works. Researchers will check if it helps improve motor skills (like movement and coordination) and if it increases levels of an important enzyme called Arylsulfatase A (ARSA) in the blood, which is often missing or low in people with MLD. This research is trying to find better ways to manage this challenging condition.
At a glance
What is this study about?
This clinical trial is investigating a new and hopeful treatment called Libmeldy for a condition called Metachromatic Leukodystrophy, or MLD. MLD is a serious genetic disease that affects the nervous system, leading to problems with movement, thinking, and other bodily functions. This new treatment is a type of gene therapy, specifically using a patient's own blood stem cells that have been specially modified to help the body produce a missing enzyme.
The main aim of this study is twofold: first, to make sure the treatment is safe for patients. This involves carefully watching for any side effects from the processes involved, including the preparation for the gene therapy and the therapy itself. Secondly, the study wants to find out if the treatment actually works to improve the health of people with MLD. Researchers will be looking at important signs like whether patients show better movement skills and if their bodies start making more of a crucial enzyme called Arylsulfatase A (ARSA), which helps break down certain substances in the body.
They'll compare how patients in the study are doing with how other MLD patients of a similar age, who haven't had this new treatment, typically progress. They'll also check things like nerve function, brain scan results, and even a patient's IQ sometimes, over a period of up to 36 months after treatment. This thorough approach helps doctors understand the full impact of the new therapy.
Key takeaways
- This study is testing a new gene therapy called Libmeldy for MLD.
- The main goals are to check the treatment's safety and how well it works.
- It aims to improve movement and increase an important enzyme in the body.
- Participants will have regular check-ups for up to three years after treatment.
- Like all treatments, there are potential benefits and risks to consider.
Who may be eligible?
This study is open to both male and female patients of any age who have been diagnosed with Metachromatic Leukodystrophy (MLD). The research team will carefully review each potential participant's medical history and current health to make sure the treatment is suitable for them.
This means that before you can join, doctors will need to check if you meet all the specific health requirements for the study. This is to ensure your safety and that the trial collects the most accurate information about the treatment.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have been diagnosed with Metachromatic Leukodystrophy (MLD).
- I am willing to undergo preparation for gene therapy.
- I am able and willing to attend follow-up appointments for up to three years.
- I am open to having various medical tests, such as blood tests and scans.
What does participation involve?
If you decide to take part in this study, you would first undergo a process to prepare your body for the gene therapy. This involves receiving treatment to get your blood stem cells ready. Then, you would receive the Libmeldy treatment, which is given as an infusion, much like a drip. After the treatment, there will be careful monitoring and follow-up appointments over a period of up to 36 months (three years). These visits will involve various tests, including blood checks, assessments of your movement and thinking abilities, and potentially brain scans, to see how you are responding to the treatment and to keep an eye on your overall health. Your commitment to these follow-up visits is important for the study.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is Metachromatic Leukodystrophy (MLD)?
MLD is a rare, inherited condition that damages the nervous system, affecting a person's movement, thinking, and other body functions.
What is Libmeldy?
Libmeldy is a new gene therapy being tested. It works by using your own blood stem cells, which are changed to help your body make a missing enzyme important for MLD.
How is Libmeldy given?
It's given as an infusion, similar to a drip, after your body has been prepared for the treatment.
How long will I be followed after the treatment?
You will be monitored for up to 36 months (three years) after receiving the treatment to check your health and how well the treatment is working.
What kind of tests will I have during the study?
You'll have various tests including blood checks, assessments of movement and thinking, and potentially brain scans.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.